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ABSTRACT
It’s a Bleed: Pediatric Hemophilia and Length of Stay, Rural vs Urban Hospitals
Daniel G. Liedl
Hemophilia is a rare genetic disorder that requires specialty care and treatment.
Pediatric patients with hemophilia have unique medical issues that may lead to permanent
disability or death if not properly diagnosed and treated in a timely manner. Due to lack of
resources and proper training of staff, rural hospitals are not equipped to properly treat pediatric
hemophilia patients. Utilizing the Healthcare Cost and Utilization Project (HCUP) Kids´
Inpatient Database (KID) of the Agency for Healthcare Research and Quality. I have found,
across all hospital types, pediatric hemophilia patients have longer lengths of stay, 2.7 days for
rural hospitals, 4.6 days for urban hospitals, and 5.1 days for teaching hospitals, compared to the
national mean for pediatric LOS of 1.8 days (Heys et al. 2017).
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Introduction
Hemophilia is a rare genetic disorder that requires specialty medical treatment and care.
This specialty care and treatment requires special training for physicians, hospital staff and
patients, to properly treat the hemophilia. Healthcare providers who are not properly trained may
misdiagnose or not understand how to treat hemophilia, causing a delay of a necessary treatment.
A delay in treatment can be catastrophic for a person with hemophilia. They can suffer long term
pain, disability, and even death with delayed or improper treatment.
The NHF (2019), recommends “Individuals with bleeding disorders should be triaged
urgently as delays in administering appropriate therapy, such as infusion of factor concentrate,
can significantly affect morbidity and mortality” and “administration of clotting factor
replacement to the patient should not be delayed waiting for a consultation.”
Inequality between rural and urban hospitals, in resources and specialty staff, may lead to
delays in treatments and diagnosis for pediatric patients with hemophilia. These delays can lead
to increased length of stays or transfer to another hospital for better treatment. This may cause
pain, suffering, and possibly death while the patient waits for proper treatment.
Although many studies considered length of stay, very few looked at pediatric
hemophilia patients. Yeung et al. (2016) stated, “There were a paucity of data from the studies
to group by disease severity [… and] age (in particular paediatric and geriatric groups” (39). And
Soucie et al. (2000) pointed out, “No studies have directly examined the associations between
mortality and factors related to medical management, such as care received in HTCs
[Hemophilia Treatment Center]” (437). This study adds to the knowledge on pediatric
hemophilia.
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Due to the unique nature of hemophilia and how it is diagnosed, I posit pediatric patients
in rural hospitals, with hemophilia, will have longer length of stays due to lack of resources and
staff unfamiliar with hemophilia. Utilizing the Healthcare Cost and Utilization Project (HCUP)
Kids´ Inpatient Database (KID) of the Agency for Healthcare Research and Quality, this study
examines variables associated with inpatient admissions for pediatric hemophilia patients in
rural, urban, non-teaching and urban, teaching hospitals for 2009, 2012, and 2016. I test whether
type of hospital is associated with length of stay.
Literature Review
Hemophilia:
Hemophilia is a rare genetic bleeding disorder found on a recessive x chromosome that
leads to deficiencies of clotting factors, specifically hemophilia A (factor VIII deficiency) and
hemophilia B (factor IX deficiency) for this study (Mirchandani et al. 2011; Soucie et al. 2000;
Yan and Kung 2013). Since it is a recessive x chromosome it most often passed from the mother
to her child and usually expresses in male children due to hemizygosity where the male has one x
chromosome, from the mother, and one y chromosome, from the father. Females, who have two
x chromosomes, may have hemophilia but only if both parents passed on a recessive x
chromosome. This would mean the father had to have hemophilia and the mother either had
hemophilia or was a carrier (Flantzer 2021; Pemberton 2011). See Figure 1. This has led to many
in the medical field who dismiss the idea of a female who has hemophilia and lack of diagnoses
or proper treatment for females.
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Figure 1
How Hemophilia is Inherited
(Source: http://www.unofficialroyalty.com/royal-illnesses-anddeaths/hemophilia/what-is-hemophilia/)
A diagnosis of hemophilia or other type of bleeding disorder happens when there is a
deficiency of one of 13 blood proteins known as factors. These factors affect blood clotting and
hemostasis within the human body. The most common type of factor deficiency is hemophilia A
or Factor VIII deficiency, with approximately 80 - 85% of cases, followed by hemophilia B or
Factor IX deficiency (NHF 2020; Yan 2013).
Hemophilia is treated with an antihemophilic factor products, known as “Factor,” in the
community. This Factor product has, in the past, been produced through a pooled blood
procedure made by using tens of thousands of units of donated blood. Factor is isolated from the
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pooled blood and made into a concentrate that is used for treatment. Synthetic products have
been produced in vitro, using cell culture lines that do not contain human blood since 1992. The
Factor concentrate used as an intravenous infusion to treat hemophilia, either by the person with
hemophilia or a trained individual (DePrince 2017; NHF 2020; Resnik 1999; Weinberg and
Shaw 2017).
There are conflicting data concerning the number of people with hemophilia in the
United States. Soucie et al. (1998), collected data from Hemophilia Treatment Centers in six
states and determined, through extrapolation, there were approximately 13,000 people with
hemophilia in the United States. The CDC (2019) reports in 1994 there were around 17,000 and
in 2019, it is estimated that around 20,000 people have Hemophilia in the United States. Another
study by Iorio et al. (2019), using data from six countries with universal healthcare, estimated the
numbers to be 17.1/100,000 males worldwide which extrapolates to ~ 20,000 males with
hemophilia in the United States. Lastly, the CDCa (2019) provides numbers of people with all
types of hemophilia being treated at all the Hemophilia Treatment Centers in the United States,
from the years 2012 through 2018 ranging from the lowest in 2018 of 21,861 to the highest in
2017 of 34,346.
In 1975 Congress passed the Public Health Service Act which contained provisions that,
“established and funded a network of Hemophilia Diagnostic and Treatment Centers throughout
the United States” (Smith et al. 1984:616). These centers became Hemophilia Treatment Centers
or HTCs. Mirchandani et al. (2011), referred to HTC’s when they stated, “HTCs effectively
function as sentinel sites for passive surveillance of hemophilia and other bleeding disorders”
(s355). And McCavit et al. (2011) pointed out, “hemophilia treatment centers, … dramatically
improve costs, service utilization, and functional outcomes” (377).
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Hemophilia Treatment Centers provide comprehensive treatment for anyone with a
diagnosed bleeding disorder. The staff at these HTCs are highly trained in the care and treatment
of hemophilia and bleeding disorders (Mirchandani et al. 2011; Soucie et al. 2000; Yeung et al.
2016; Yan and Kung 2013). Smith et al. (1984:616) states,
•
•
•
•
•
•

The minimum services provided by each center were:
A coagulation laboratory of recognized high standards;
A blood bank providing all of the blood components needed by
hemophiliacs;
A multidisciplinary hemophilia care team including a hematologist, an
internist, a pediatrician, an orthopedic surgeon, a physical therapist, a
dentist, a social worker, and a registered nurse;
Formal linkages with mental health, genetic counseling, and rehabilitative
services;
A training course in self-therapy (home care) and updated hemophilia
concepts for patients and family members;
An outreach program to enable every hemophiliac within the area served
to receive services of the program

Much of the literature estimates approximately two thirds of hemophilia patients receive
at least some of their treatment at HTCs (Mirchandani et al. 2011; Soucie et al. 2000; Yeung et
al. 2016). Common issues faced by the person with hemophilia include: associated costs of
medicines and lost productivity, treatment side effects, arthropathy of joints leading to physical
disabilities and mobility problems, chronic pain, and a shorter projected lifespan (Barkdull 2014;
DePrince 2017; Resnik 1999; Weinberg and Shaw 2017; White and Cunningham 1991).
According to Soucie et al. (2000), “survival is significantly greater among hemophiliacs who
receive medical care in HTCs” (437).
Hemophilia Diagnosis and Treatment:
A reliable method of diagnosing hemophilia was not available until the 1950’s when
scientists developed clotting factor assays, specifically a “thromboplastin generation test” in
1953 and at the same time frame the “partial thromboplastin time” test was also developed
(Pemberton 2011:92). According to the Center for Disease Control (CDC b 2020) and Dr.
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Samuel Merrill (pers. comm.) currently, several methods are utilized for hemophilia diagnosis,
they include complete blood count (CBC), activated partial thromboplastin time (aPTT),
prothrombin time (PT), fibrinogen, and specialized clotting factor tests and factor assays.
The CBC can tell how many red blood cells are in the blood and if the number is low, it
may indicate excess bleeding. An abnormal aPTT could indicate a deficiency of a clotting factor
such as Factor VIII or IX. A PT tests for different clotting factor deficiencies. And a Fibrinogen
test for the ability to form clots (CDC b 2020; Dr. Merrill (pers. comm); Pemberton 2011).
According to Dr. Samuel Merrill (pers. Comm), there are currently more than 50 different
recognized bleeding disorders, hemophilia A and hemophilia B are two of the more prevalent.
The clotting factor assays will provide the type of specific factor deficiency, for example
factor VIII (hemophilia A) or factor IX (hemophilia B) and the severity of the hemophilia (CDC
b 2020; Dr. Merrill (pers. comm); Pemberton 2011). Severity indicates the level of clotting factor
deficiency. The levels include, severe, which is less than 1% of normal, moderate, which is 15% of normal, and mild, which is 6- 30% of normal (Soucie 2000). According to Kulkarni and
Souci (2011), “Approximately two-thirds of persons with hemophilia have severe disease; 15%
have moderate disease; and 20% have mild disease” (737).
Hemophilia treatment has come a long way in the last 100 years. From no special
treatment other than poultices, rest, heat, and ice to whole blood transfusions, to cryoprecipitate
(the sludge scraped off the bottom of thawed plasma), to “Factor” (a concentrated form of the
specific clotting factor, such as factor VIII or IX, made from pooled donated blood or in vitro), to
the newest gene therapy (Barkdull 2014; DePrince 2017; NHF 2020; and Pemberton 2011).
Today most people with severe hemophilia treat prophylactically with recombinant factor
concentrates. The individual, parent or someone trusted are taught to infuse through venipuncture

7
in a vein or a central line. Two regularly used central lines include a peripherally inserted central
line (PICC line) which, according to the Mayo Clinic (2021), is a thin tube inserted into a vein in
the arm, and rarely in the leg or neck, and threaded through larger veins close to the heart. The
PICC makes it easier to infuse and saves the individual from numerous venipunctures. And a
Port, which, according to The National Cancer Institute (2022), is a device used for infusions and
drawing blood that is inserted under the skin in the upper chest and is attached to a thin tube that
is inserted into a large vein and placed near the heart. Once they learn how to self-infuse, they
are then provided with the product and essential accessories to perform this on a regular basis
(Kulkarni and Soucie 2011; NHF 2020; Pemberton 2011).
Prophylactic treatment is done at home by the individual or a trusted person, two or more
times a week to maintain factor levels in the normal range and is meant to be proactive in the
prevention and treatment of bleeds. The process of prophylactic treatment not only requires
special training but also maintaining sterile procedures and making arrangements for proper
disposal of infusion equipment, such a needles and syringes. As Bertamino et al. (2017) report,
“prophylactic treatment that is started early with clotting-factor concentrates has been shown to
prevent hemophilic arthropathy and is, therefore, the gold standard of care for hemophilia A and
B in most countries with adequate resources” (1).
Pediatric hemophilia:
Kulkarni and Soucie (2011) sum up pediatric hemophilia treatment when they state,
“hemophilia is a serious congenital bleeding disorder that requires early diagnosis, intensive
family and patient education, and regular comprehensive care to prevent life-threatening
complications and potentially lifelong disability” (743). Pediatric hemophilia has different
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treatment requirements than adults and requires closer personal care to ensure continuity of
therapy as they grow up.
Neonatal patients may have issues with intracranial hemorrhages due to delivery method
or just regular head bumps from everyday activity. They also may manifest bleeds during
circumcision, teething, heel pricks at birth or even venipuncture; older pediatric patients with
hemophilia manifest with injuries to joints or soft tissue due to falls, bumps, scrapes from being
children (Bertamino et al. 2017; Ettingshausen et al. 2001; Kulkarni and Souci 2011).
It is imperative for pediatric bleeds to be treated immediately or the bleed may cause
irreparable damage to the brain, joints, and or soft tissue and could even cause death, if left
untreated. Kulkarni and Soucie (2011) state,
“bleeding episodes in hemophilia often result in physical (pain, hemophilic
arthropathy, organ dysfunction) or mental impairments leading to restriction in
activities including school and social participation that affect education and QOL.
The major functional impairment in mobility is secondary to limited joint ROM
with BMI as a significant predictor” (742).
Research has shown the earlier a pediatric patient with hemophilia is treated the better the
long-term outcomes. By treating pediatric hemophilia patients in a timely manner, the more
likely they are to avoid long-term damage and disability: “The goal must be to avoid bleeding
complications and joint damage in the pediatric age in order to enable the hemophiliac patient to
reach adulthood as healthy as possible” (Bertamino et al. 2017:8).
Rural vs non-Teaching, Urban vs Urban Teaching Hospitals
The literature shows a discrepancy in treatment options concerning rare disorders,
including hemophilia, between rural and urban hospitals (teaching and non-teaching). Due to
these discrepancies, treatment is delayed, and complications arise requiring longer length of stays
(LOS) and/or transfer to urban hospitals (Akintoye et al. 2017; Robinson and Luft 1985; Vohra
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et al. 2020). As Vohra et al. (2020) points out, “rural-urban disparities also present in children’s
health outcomes” (493) and “higher mortality incidence exists in rural counties compared to
urban counties for infants, children, and young adults” (493)
Research further shows LOS is affected by various conditions, including diagnosis,
regulations, bed size (number of beds in the hospital), costs, and physician/patient choice.
Studies have shown urban hospitals usually have longer average length of stays than rural
hospitals, with urban teaching hospitals regularly having the longest average length of stay.
While LOS appears to be longer in non-teaching and teaching urban hospitals, rare diseases
being treated in rural hospitals seem to show longer LOS or transfer to urban hospitals when the
rural hospital is unable to provide the necessary care (Jatwani et al. 2019; Lorch et al. 2004;
Singh and Ladusingh 2010): “This suggests that 2 distinct processes are at work, i.e., routine
treatment of patients with uncomplicated conditions who are discharged promptly and treatment
of patients with special complications that delay discharge” (Lorch et al. 2004:e401).
Lee et al. (2003) states, “length of stay (LOS) is an important measure of hospital activity
and health care utilization” (681) and “length of stay (LOS) is an important measure of health
care utilization and determinant of hospitalization cost” (681). Hospital administration,
physicians, and costs factor into services available at hospitals. Services and amenities factor into
patient satisfaction and hospitals in large markets usually have more services and amenities due
to competition while smaller hospitals are unable to compete because of costs of equipment and
other resources (Robinson and Luft 1985).
As a result of hospitals trying to control rising costs some services and overall quality of
healthcare may have suffered: “Systematic clinical cost-containment efforts have increased in
response to the need to control health care expenditures” (Weingarten et al. 1998:33). This may
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have led to rural healthcare lacking proper resources and lacking specialist providers. Which
leads to, “higher mortality incidence exist[ing] in rural counties compared to urban counties for
infants, children, and young adults” (Vohra et al. 493)
Because the “potential differences between rural and urban hospitals may influence the
efficiency of care received by hospitalized children” (Lorch et al. 2004:e400), pediatric patients
with hemophilia will suffer. Leyland and Andrew (1997) also point out that there is “a negative
correlation between residuals for length of hospital stay and those for readmission rates
suggesting that pressures to reduce lengths of stay may have the effect of increasing rates of
readmission” (141) and “for fixed bed numbers - the length of stay will affect and be affected by
admission rates and that readmission rates will have a similar relationship” (141).
Due to the complex nature of hemophilia, hospitals must possess proper resources and
trained staff. In most instances, rural hospitals do not possess these resources or training. This
should lead to longer length of stays for pediatric patients with hemophilia. With longer lengths
of stay, pediatric patients with hemophilia suffer for, first, lack of or delay in proper treatment
and second, quality of life.
Hypotheses
H1 - Pediatric patients with hemophilia in rural hospitals will have longer length of stays
compared to urban hospitals.
Methods
Data – This study utilized the Healthcare Cost and Utilization Project (HCUP) Kids´
Inpatient Database (KID) of the Agency for Healthcare Research and Quality. The HCUP Kids
dataset contains over 4 million pediatric discharges and is part of HCUP which is one of the
largest data collections of longitudinal hospital care in the United States, developed by a
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partnership consisting of Federal, State and Industry. The Federal government along with State
data organizations, hospital organizations, and private data organizations created the dataset as a
“national information resource of encounter-level healthcare data.” HCUP has been compiling
data since 1988 with “The Kids’ Inpatient Database” being collected since 1997 and contains a
sample of nationwide pediatric inpatient discharges.
This study examines inpatient discharges for pediatric hemophilia patients in 2009, 2012,
and 2016. For this study, I only consider length of stays with a diagnosis of either hemophilia A
or hemophilia B.
Cases – Cases were identified using ICD-10 diagnosis code 286.0 Congenital factor VIII
deficiency (hemophilia A) and 286.1 Congenital factor IX deficiency (hemophilia B). All
variable descriptions are copied directly from the HCUP KID dataset codebook
(https://www.hcup-us.ahrq.gov/db/nation/kid/kiddde.jsp).
Dependent Variable
LOS (length of hospital stay) is calculated by subtracting the admission date from the
discharge date. Same-day stays are coded as 0. Leave days are not subtracted. Ranges
from 0 up to 228 days.
Independent Variable
Hospital Location indicates the location and teaching status of hospital. A hospital is
considered a teaching hospital if it has one or more Accreditation Council for Graduate
Medical Education (ACGME) approved residency programs, is a member of the Council
of Teaching Hospitals (COTH) or has a ratio of full-time equivalent interns and residents
to beds of .25 or higher. Rural hospitals were not split according to teaching status,
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because rural teaching hospitals were rare. 1 = rural, 2 = urban nonteaching, and 3= urban
teaching.
Control Variables
AGE (age at admission) is calculated from the patient’s date of birth and the admission
date, specifically ages 0 - 20.
FEMALE (sex of patient) is provided by the data source. All non-male, non-female (e.g.,
"other") values were set to missing by the data source (0 = Male and 1 = Female).
RACE (race of patient), 1 = White, 2 = Black, 3 = Hispanic, 4 = Asian or Pacific Islander,
5 = Native American, or 6 = Other.
Median Household Income provides a quartile classification of the estimated median
household income of residents in the patient's ZIP Code, 1= 0 – 25th quartile, 2 = 26th –
50th quartile, 3 = 51st – 75th quartile, and 4 = 76th – 100th quartile.
Number of Hospital Beds (see Table 1) are based on the number of hospital beds, the
hospital's location, and teaching status. Bedsize assesses the number of short-term acute
care beds set up and staffed in a hospital. Hospital information was obtained from the
American Hospital Association Annual Survey of Hospitals. The hospital's bedsize
categories are defined using region of the U.S., the urban-rural designation of the
hospital, and the teaching status of the hospital. 1 = small, 2 = medium and 3 = large
based on the following table from the HCUP KIDS code book (https://www.hcupus.ahrq.gov/db/vars/hosp_bedsize/kidnote.jsp).
Table 1. HCUP KIDS Hospital Bedside Definition
Hospital Bedsize
Location and Teaching Status
Small

Medium

Large
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NORTHEAST REGION
Rural

1-49

50-99

100+

Urban, nonteaching

1-124

125-199

200+

Urban, teaching

1-249

250-424

425+

MIDWEST REGION
Rural

1-29

30-49

50+

Urban, nonteaching

1-74

75-174

175+

Urban, teaching

1-249

250-374

375+

SOUTHERN REGION
Rural

1-39

40-74

75+

Urban, nonteaching

1-99

100-199

200+

Urban, teaching

1-249

250-449

450+

WESTERN REGION
Rural

1-24

25-44

45+

Urban, nonteaching

1-99

100-174

175+

Urban, teaching

1-199

200-324

325+

Hospital Control The control/ownership of the hospital is operationalized as: 1 =
government, non-federal, 2 = private, non-profit, and 3 = private, investor owned.
Hospital Region indicates the hospital's census region (1 = Northeast, 2 = Midwest, 3 =
South, and 4 = West).
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Patient location represents a six-category urban-rural classification scheme for U.S.
counties developed by the National Center for Health Statistics (NCHS) especially for
use in health care research. The classification emphasizes urban distinctions and is unique
in differentiating between central and fringe counties of large metropolitan areas. Smaller
metropolitan counties are subdivided by population. Non-metropolitan counties are
divided simply into micropolitan and non-core categories. The county classifications are
based on the Office of Management and Budget (OMB) metropolitan/micropolitan
assignments. (1 = Central counties of metro areas of >= 1 million population, 2 = Fringe
counties of metro areas of >= 1 million population, 3 Counties in metro areas of 250,000999,999 population, 4 = Counties in metro areas of 50,000-249,999 population, 5 =
Micropolitan counties, and 6 = Not metropolitan or micropolitan counties).
Hospital STRATUM (Stratum used to post-stratify hospitals) identifies rural, urban nonteaching, and urban teaching hospitals.
Patient Disposition indicates the disposition of the patient at discharge, 1 = routine, 2 =
transfer to short-term hospital, 5 = transfer to other (skilled nursing, intermediate care,
another type of facility), 6 = home health care, 7 = against medical advice (AMA), codes
20 = died and 99 = discharged alive destination unknown were recoded into one category
under 99 due to only 3 cases having died.
TRAN_IN indicates that the non-newborn patient was transferred into the hospital (0 =
Not transferred in or newborn admission indicated, 1 = patient transferred in from
different acute care hospital, 2 = Transferred in from another type of health facility).
Payer indicates the expected primary payer (1 = Medicare and 2 = Medicaid recoded into
one category under 1, 2 = private insurance, 4 = self-pay, codes 5 = no charge and other).
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Statistical Analyses – I present descriptive statistics first followed by multivariate Poisson
regression models since my outcome is a count variable (LOS). Missing cases were deleted
listwise resulting in a sample size of 4,645 in-patient stays for pediatric hemophilia patients. Data
is weighted to be representative of pediatric discharges from U.S. community, non-rehabilitation
hospitals.
Results
Table 2. Descriptive Statistics for Patient-Level Variables (N=4,645)
Mean or %
SD min/max
LOS
5.00
9.12
0/228
Age
7.90
6.80
0/20
Sex
Male
Female

95%
5%

White
Black
Hispanic
Asian/Pacific Islander
Native American
Other

49%
17%
25%
3%
1%
5%

Race

Median Household Income
0-25%
26-50%
51-75%
76-100%

31%
25%
22%
22%

Patient Location, Rural/Urban
Central Metro >= 1 million
Fringe Metro >= 1 million
Metro 250K-999,999K
Metro 50K-249,999K
Micropolitan
Non-Metro/Micro

37%
22%
20%
7%
9%
5%
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Primary Payer
Medicare/Medicaid
Private Insurance
Self-Pay
No Charge/Other

55%
37%
2%
6%

Table 2 presents the descriptive statistics for the patient-level variables. The mean for length
of stay is 5 days with a standard deviation of 9.12 days. Length of stay ranged from zero days up
to 228 days. This is much longer than the national mean for pediatric LOS of 1.8 days (Heys et
al. 2017). The mean age of pediatric patients was 7.9 years with a standard deviation of 6.8
years. Age range was newborn through 20 years of age. The sex of pediatric patients was
overwhelmingly male at 95% with female at 5%. This is not out of the ordinary since hemophilia
is a recessive x chromosome disorder and usually presents in males. Racial makeup of pediatric
hemophilia patients was 49% White, 17% Black, 25% Hispanic, 3% Asian/Pacific Islander, 1%
Native American, and 5% reported as other. This racial makeup is different from the 2019
Census Bureau data which show the population 76% White, 13% Black, 19% Hispanic, 6%
Asian/Pacific Islander, and 1% Native American. Soucie et al. (1998) found that the incident
rates of hemophilia were similar among whites, Blacks, and Hispanics. Yet these findings point
to a difference in hospitalizations based on ethnicity. The difference cannot be just due to the 5%
reported other in these findings. The income quartiles ranging from 31% in the 0-25 quartile,
25% in the 26-50 quartile, 22% in the 51-75 quartile, and 22% in the 76-100 quartile. With the
US Census reporting the 26-50 quartile being the median for the country.
Looking at patient location, 86% of inpatient stays were from patients who live in
metropolitan areas with populations over 50,000, 9% were from micropolitans, and 5% were
from non-metropolitan/micropolitan, which for this study is considered rural. The other variable
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was type of payee. Medicare/Medicaid accounted for 55% of coverage, private insurance was
37%, 2% were self-pay, and 6% had no charge or other. Insurance or type of payee may
contribute to difference in length of stay or type of hospital used.
Table 3 presents the descriptive statistics for the hospital-level variables. Bedsize of
hospitals in the study ranged from the smallest with 10% of pediatric hemophilia patients, 20%
in the medium category, and the majority, 70%, in the large category. This finding may show the
majority of hemophilia patients are seen or transferred to large urban teaching hospitals. In terms
of type of hospital, 2% of inpatient stays were at rural hospitals, 9% were at urban non-teaching
hospitals and the majority, 89%, were at urban teaching hospitals. Again, this may point to
pediatric hemophilia patients being transferred to these large urban teaching hospitals.
When looking at hospitals by region, 17% of pediatric hemophilia in-patient stays were in the
Northeast, 20% were in the Midwest, 37% in the South, and 26% in the West. In terms of
transfer between hospitals, on discharge, 89% of pediatric hemophilia patients were routinely
discharged, 2% were transferred to another short-term hospital, 1% were transferred to other
facilities like skilled nursing or rehabilitation hospitals, and 8% to home healthcare. The findings
for pediatric hemophilia patients being transferred into another hospital, show 91% with no
transfer, 8% were transferred in from another acute care hospital, and 1% were transferred in
from another type of facility. In terms of hospital control/ownership, 13% of hospitals were
public hospitals, 80% were private non-profit hospitals, and 7% were private for-profit hospitals.
Table 3. Descriptive Statistics for Hospital-Level Variables (N=4,645)
Hospital Location
Rural
2%
Urban, Non-teaching
9%
Urban, Teaching 89%
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Hospital Bedsize
Small
Medium
Large

10%
20%
70%

North East
Midwest
South
West

17%
20%
37%
26%

Routine
Transfer to Short-term hospital
Transfer to other
Home Health

89%
2%
1%
8%

No Transfer
Transfer in from Acute Care
Transfer in Other

91%
8%
1%

Hospital Region

Patient Disposition

Transfer Into

Hospital Control
Gov
Private, non-profit
Private

13%
80%
7%

I’m interested in whether type of hospital is associated with length of stay. To start, I
examine mean length of stay by type of hospital (see Table 4). I find that urban hospitals,
whether teaching or nonteaching, have longer lengths of stay for pediatric hemophilia patients
compared to rural hospitals: mean LOS is 2.7 days for rural hospitals, 4.6 days for urban
hospitals, and 5.1 days for teaching hospitals. This is inconsistent with Hypothesis 1. Across all
hospital types, pediatric hemophilia patients have longer lengths of stay compared to the national
mean for pediatric LOS of 1.8 days (Heys et al. 2017).
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Table 4. Mean LOS by type of hospital
Hospital
Rural
Urban Non-teaching
Urban Teaching

Mean
2.696
4.617
5.060

Table 5 presents Poisson regression models predicting length of stay. Incidence Rate
Ratios are presented, such that values above one reflect an increased rate of LOS (a longer LOS)
and values below one reflect a decreased rate of LOS (a shorter LOS). There is a significant
association between age and LOS in hospital as well as sex and LOS. When age increases by one
year, the rate ratio for length of stay is expected to decrease by a factor of 0.9908, while holding
the other variables constant in the model. Compared to males, females have a rate 1.9042 times
greater for LOS net of the other variables.
When looking at race, Hispanic patients had a 1.1521 higher rate of LOS compared to
White patients, while holding the other variables constant in the model. Looking at income
quartiles, the rate for LOS is 0.8668 times lower for the 2nd quartile income compared to the 1st
quartile income. Transfers from other acute care hospitals had a 1.5350 greater rate for LOS
compared to no transfers, while holding the other variables constant in the model. There was no
significance difference in LOS for transfers from other medical facilities.
I also looked at hospital control and found that private non-profit hospitals had a 0.8188
lower rate of LOS compared to government run hospitals, while holding the other variables
constant in the model. Similarly, private for-profit hospitals had a significantly lower rate of LOS
compared to government run hospitals, net of the other variables.
When considering LOS, I also looked at the disposition of patients on release. While
there was no significant difference for transfers to short term care facilities (p= 0.886), I did find
a significant association for transfer to other health care facilities (p=0.000) such as rehabilitation
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hospitals and nursing care facilities and to home health care. Compared to routine discharge,
transfers to other healthcare facilities had a 2.3702 times greater rate of LOS and transfers to
home healthcare had a 1.8538 times greater rate of LOS (Table 5).
I was also interested in looking at who paid the hospital charges. Patients with private
health insurance had a 0.8958 times lower rate of LOS compared to Medicare or Medicaid, while
holding the other variables constant in the model. There was no significance difference in rate of
LOS found for self-pay or other pay, such as no charge. No significance differences in rates of
LOS were found for bedsize of hospitals or hospital region.
When I looked at location of hospital, rural, urban non-teaching, and urban teaching and
LOS, I found a significant difference for urban non-teaching and urban teaching hospitals when
compared to rural hospitals. Compared to rural hospitals, urban non-teaching hospitals had a
1.7414 greater rate of LOS and urban teaching hospitals had a 1.7680 greater rate of LOS, while
holding the other variables constant in the model.
Table 5. Poisson Regression Models Predicting LOS, Incidence Rate Ratios Presented (N=4645)
Variable

Ref Category

IRR

SE

0.9908*

0.0044

1.9042**

0.3233

Black

1.0292

0.0705

Hispanic

1.1521*

0.0756

Asian/Pacific Islander

1.2675

0.2388

Native American

1.1469

0.1704

Other

0.9771

0.1012

2nd Quartile

0.8668*

0.0554

3rd Quartile

0.9135

0.0644

4th Quartile

0.9963

0.0796

Medium

1.1376

0.1091

Age
Sex

Male

Race

White

Income

Bedsize

1st Quartile

Small
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Region

Central Urban

Tran In

No Transfer

Disposition

Payer

Hospital Location

1.0182

0.0717

Midwest

0.9588

0.0910

South

0.9668

0.0815

West

0.9524

0.0870

0.9874

0.0239

Acute Care Hosp

1.5350**

0.1329

Other

1.3954

0.4354

Private Non-profit

0.8188*

0.0755

Private For-profit

0.7321**

0.0823

Transfer Short-term Hosp

1.0412

0.2938

Transfer Other

2.3702**

0.4807

Home

1.8538**

0.1556

Private

0.8958*

0.0501

Self

1.0196

0.1569

Other

0.9816

0.1004

Urban Non-teaching

1.7414**

0.2403

Urban Teaching

1.7680**

0.2162

Northeast

Patient Location

Hospital Control

Large

Government

Routine Discharge

Medicare/Medicaid

Rural

Note: ** = p< 0.01, * = p<0.05

Discussion
In this study I looked at data from the HCUP Kids’ Inpatient Database (KID), Healthcare
Cost and Utilization Project (HCUP). Specifically pediatric hemophilia patients’ length of stay
(LOS) in rural vs urban non-teaching vs urban teaching hospitals. As stated in my hypothesis, I
posited pediatric hemophilia patients would have a longer LOS in rural hospitals compared to
urban hospitals. My hypothesis was based on research finding that rural hospitals have fewer
specialists, less resources, and lack training in rare disorders. However, I found the opposite.
These findings may highlight rural hospitals understanding their limitations and quickly
transferring pediatric hemophilia patients to urban hospitals better equipped to handle this
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disorder. It may also be that pediatric hemophilia patients, aware of the limitations in rural
hospitals, will travel to better equipped and knowledgeable hospitals. This raises many questions
for further research, such as what are the underlying mechanisms associated with hemophilia
patients in rural hospitals having shorter lengths of stay compared to hemophilia patients in
urban hospitals.
As pointed out in Table 3 above, there was an increased mean LOS for pediatric
hemophilia patients compared to the national mean for pediatric LOS (Heys et al. 2017). Why
do pediatric patients with hemophilia spend 3 days more on average in hospital than other
pediatric patients? The longer LOS for pediatric hemophilia patients could point to several
factors leading to this increase. First, pediatric hemophilia patients may have more complicated
medical issues related to hemophilia. Second, pediatric hemophilia patients may require more
intensive treatment and monitoring that is not possible as an outpatient. And third, hospitals and
staff may not be properly trained or prepared and lack the resources to deal with the specific
needs of hemophilia. As has been pointed out, hemophilia is a rare genetic disorder that requires
specialty medical treatment and care. This care and treatment require additional training for
physicians, hospital staff and patients, to properly treat hemophilia. Healthcare providers who are
not properly trained may misdiagnose or not understand how to treat hemophilia, causing a delay
of a necessary treatment. The NHF (2019), recommends “Individuals with bleeding disorders
should be triaged urgently as delays in administering appropriate therapy, such as infusion of
factor concentrate, can significantly affect morbidity and mortality.” A delay in treatment can be
catastrophic for a person with hemophilia. They can suffer long term pain, disability, and even
death with delayed or improper treatment.

23
These findings point to the need for more training and resources for hospital staff and
hospitals. The National Hemophilia Foundation and the Hemophilia Treatment Centers in the
United States can and will provide training when requested. There are programs in place that will
visit and train staff. This training consists of proper diagnosis and symptomatic indicators of a
hemophilia related condition. The training will also specify the urgency of early treatment as per
MASAC Document 257 - Guidelines for Emergency Department Management of Individuals with
Hemophilia and Other Bleeding Disorders (NHF 2019).
Another area that raised questions was the difference in LOS by sex and age. Is there a
difference in diagnosis between male and female hemophilia patients? I would posit there may
be a lack of knowledge about hemophilia and the treatment of hemophilia in the hospital system.
While it was not possible to ascertain that data from this data set, it may be available elsewhere
and should be studied.
Another interesting finding was that Hispanic pediatric hemophilia patients have longer
lengths of stay than their White counterparts. This follows what Lasser et al. (2006) found that
minorities and immigrants are less likely to have health insurance, seek health care less, and
receive improper treatment when sought. Also, the fact that White patients only made up 49% of
the sample compared to 76% for the general population is interesting. It is possible that White
pediatric patients have better access to preventative care and treatment and thus, require less time
in the hospital compared to Hispanic pediatric patients. This would be another area that should
be further researched in the pediatric hemophilia community.
Strengths and Limitations
The strength of this study lies in the size and breadth of the data set—it covers 50 states
and over 4 million pediatric discharges, including 4,645 pediatric hemophilia discharges. Given
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that hemophilia is a rare condition, the large sample size offered by this dataset is an advantage.
The study also has several limitations. The data set does not have “transfer out” information for
all the years of data I used. There was no way to indicate whether a hospital had a Hemophilia
Treatment Center, which may affect LOS. This study was only able to look at rural/urban nonteaching/urban teaching hospital types. Resources, training, specialization of the hospitals were
not a part of the data to maintain the anonymity of the hospitals. This information would have
added an extra layer of data to understand why LOS was longer for pediatric hemophilia patients
in urban hospitals. Another limitation would be the lack of severity of diagnosis on admission
which may have a direct effect on LOS and transfer to an urban or teaching hospital. The lack of
admission diagnoses also precludes ascertaining the severity of hemophilia and reason for
treatment.
Further research is required to examine the differences more fully between male and
female pediatric hemophilia patients in their length of stays. It is also important for future
research to examine how lack of resources, training, and specialization in rural hospitals affect
those with hemophilia or other rare disorders and how race and income affects treatment for
hemophilia.
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